世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000031297

創薬サービス市場-2026年までの世界予測

MarketsandMarkets

Drug Discovery Services Market -Global Forecast to 2026

発刊日 2022/02

言語英語

体裁PDF/281ページ

ライセンス/価格281ページ

0000031297

Single
5-user
Corporate
Global

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

創薬サービス市場:プロセス別(ターゲットの選択、検証、リードジェネレーション)、種類別(化学、生物学)、薬剤の種類別(低分子薬、生物製剤)、治療領域別(腫瘍学、神経学)エンドユーザー別(製薬、バイオテクノロジー)- 2026年までの世界予測

世界の創薬サービス市場は、2021年の161億ドルから、2026年までに314億ドルに達し、2021年から2026年までのCAGRは14.3%と推定されます。医薬品およびバイオ医薬品業界における研究開発費の増加、分析試験サービスのアウトソーシングに対する需要の増加、希少疾患および希少疾病用医薬品の研究に関する戦略、医薬品の自社開発の高いコストによって、創薬サービス市場に新たな収益源が生まれています。一方で、創薬や動物の使用に対する厳しい規制によって市場の成長がある程度抑制される可能性があります。 熟練した専門家の不足が創薬サービス事業者にとって課題となります。

レポート詳細

目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 26)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 30)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 COVID-19 SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 42)

4 PREMIUM INSIGHTS (Page No. - 46)
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY (2020)
4.3 DRUG DISCOVERY SERVICES MARKET SHARE, BY TYPE (2020)
4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
4.5 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW (Page No. - 50)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing R&D expenditure in the pharma & biopharma industry
5.2.1.2 Increasing demand for outsourcing analytical testing
5.2.1.3 Initiatives for research on rare diseases and orphan drugs
5.2.1.4 High cost of in-house drug development
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulations governing drug discovery and animal usage
5.2.3 OPPORTUNITIES
5.2.3.1 Growth in drugs and biologics market despite COVID-19 pandemic
5.2.3.2 Rising demand for specialized testing services among end users
5.2.3.3 Patent expiry
5.2.3.4 High growth prospects in emerging markets
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled personnel
5.2.5 MARKET TRENDS
5.2.5.1 Shift in drug discovery services due to growing adoption of AI-based tools
5.2.5.2 Increased outsourcing to emerging Asian economies
5.2.5.3 CRO industry consolidation
5.2.5.4 Integrated end-to-end R&D service solution
5.3 IMPACT OF COVID-19 ON THE DRUG DISCOVERY SERVICES MARKET
5.3.1 ASSUMPTIONS - DRUG DISCOVERY SERVICES MARKET ESTIMATION AND FORECAST
5.3.2 ASSUMPTIONS - COMPANY REVENUE GROWTH
5.4 RANGES/SCENARIO
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 TECHNOLOGY ANALYSIS
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 DEGREE OF COMPETITION

6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS (Page No. - 74)
6.1 INTRODUCTION
6.2 TARGET SELECTION
6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT THE GROWTH OF THIS MARKET
6.3 TARGET VALIDATION
6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
6.4 HIT-TO-LEAD IDENTIFICATION
6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN THE MARKET
6.5 LEAD OPTIMIZATION
6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS
6.6 CANDIDATE VALIDATION
6.6.1 FUTURE MANUFACTURING SUITABILITY, SCALE-UP, COMMERCIAL VIABILITY, AND COST-EFFECTIVENESS OF CANDIDATES HEAVILY IMPACT THE LONG-TERM SUCCESS OF DRUGS

7 DRUG DISCOVERY SERVICES MARKET, BY TYPE (Page No. - 88)
7.1 INTRODUCTION
7.2 CHEMISTRY SERVICES
7.2.1 GROWING CHEMICAL & BIOCHEMICAL TESTS AND WIDE APPLICATIONS OF CHEMISTRY IN DRUG DISCOVERY ARE MAJOR FACTORS DRIVING MARKET GROWTH
7.3 BIOLOGY SERVICES
7.3.1 THE INTRODUCTION OF GENOMICS AND PROTEOMICS WILL ENHANCE MARKET GROWTH

8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE (Page No. - 94)
8.1 INTRODUCTION
8.2 SMALL-MOLECULE DRUGS
8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET
8.3 BIOLOGIC DRUGS
8.3.1 SAFETY AND MANUFACTURING CHALLENGES ASSOCIATED WITH BIOLOGICS DEVELOPMENT TO DRIVE ADOPTION OF OUTSOURCING SERVICES

9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 101)
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
9.3 INFECTIOUS & IMMUNE SYSTEM DISEASES
9.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES
9.4 NEUROLOGY
9.4.1 THE INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH
9.5 DIGESTIVE SYSTEM DISEASES
9.5.1 LARGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES IS EXPECTED TO DRIVE THE MARKET
9.6 CARDIOVASCULAR DISEASES
9.6.1 THE HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS
9.7 OTHER THERAPEUTIC AREAS

10 DRUG DISCOVERY SERVICES MARKET, BY END USER (Page No. - 119)
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE
10.2.2 TIER 1 COMPANIES
10.2.2.1 High investing capacity is the major factor driving the growth of this segment
10.2.3 TIER 2 COMPANIES
10.2.3.1 Limited investment capacity is expected to restrain the growth of this segment
10.2.4 TIER 3 COMPANIES
10.2.4.1 Tier 3 companies are smaller and have fewer technical advantages
10.3 ACADEMIC INSTITUTES
10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
10.4 OTHER END USERS

11 DRUG DISCOVERY SERVICES MARKET, BY REGION (Page No. - 131)
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market
11.2.2 CANADA
11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth
11.3 EUROPE
11.3.1 GERMANY
11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market
11.3.2 UK
11.3.2.1 Collaborations between the government and private stakeholders to support market growth
11.3.3 FRANCE
11.3.3.1 The high number of oncology research projects in France to drive market growth
11.3.4 ITALY
11.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth
11.3.5 SPAIN
11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
11.3.6 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 CHINA
11.4.1.1 China dominates the Asia Pacific market due to a robust pharmaceutical industry and the presence of prominent CROs
11.4.2 JAPAN
11.4.2.1 Government initiatives for drug innovation to support market growth in Japan
11.4.3 INDIA
11.4.3.1 Low-cost services and availability of skilled workforce and strong government support to drive market growth in India
11.4.4 SOUTH KOREA
11.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 BRAZIL
11.5.1.1 The presence of a large pool of treatment-naïve patients and short approval timeline is expected to drive market growth in this region
11.5.2 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN THE MIDDLE EAST AND AFRICA

12 COMPETITIVE LANDSCAPE (Page No. - 183)
12.1 OVERVIEW
12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
12.3 MARKET SHARE ANALYSIS
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
12.5 COMPANY EVALUATION QUADRANT
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
12.7 COMPANY SERVICE FOOTPRINT
12.8 COMPANY GEOGRAPHIC FOOTPRINT
12.9 COMPETITIVE SCENARIO
12.9.1 SERVICE LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSION

13 COMPANY PROFILES (Page No. - 196)
13.1 KEY PLAYERS
13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
13.1.1.1 Business overview
13.1.1.2 Services offered
13.1.1.3 Recent developments
13.1.1.4 MnM view
13.1.1.4.1 Key strengths/Right to win
13.1.1.4.2 Strategic choices made
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
13.1.2.1 Business overview
13.1.2.2 Services offered
13.1.2.3 Recent developments
13.1.2.4 MnM view
13.1.2.4.1 Key strengths/Right to win
13.1.2.4.2 Strategic choices made
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 WUXI APPTEC
13.1.3.1 Business overview
13.1.3.2 Services offered
13.1.3.3 Recent developments
13.1.3.4 MnM view
13.1.3.4.1 Key strengths/Right to win
13.1.3.4.2 Strategic choices made
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 THERMO FISHER SCIENTIFIC
13.1.4.1 Business overview
13.1.4.2 Services offered
13.1.4.3 Recent developments
13.1.5 PHARMARON BEIJING CO., LTD.
13.1.5.1 Business overview
13.1.5.2 Services offered
13.1.5.3 Recent developments
13.1.6 EVOTEC SE
13.1.6.1 Business overview
13.1.6.2 Services offered
13.1.6.3 Recent developments
13.1.7 EUROFINS SCIENTIFIC SE
13.1.7.1 Business overview
13.1.7.2 Services offered
13.1.7.3 Recent developments
13.1.8 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
13.1.8.1 Business overview
13.1.8.2 Services offered
13.1.9 PIRAMAL ENTERPRISES LIMITED
13.1.9.1 Business overview
13.1.9.2 Services offered
13.1.9.3 Recent developments
13.1.10 SYNGENE INTERNATIONAL LIMITED
13.1.10.1 Business overview
13.1.10.2 Services offered
13.1.10.3 Recent developments
13.1.11 CURIA GLOBAL INC.
13.1.11.1 Business overview
13.1.11.2 Services offered
13.1.11.3 Recent developments
13.1.12 GENSCRIPT BIOTECH CORPORATION
13.1.12.1 Business overview
13.1.12.2 Services offered
13.1.12.3 Recent developments
13.1.13 JUBILANT PHARMOVA LIMITED
13.1.13.1 Business overview
13.1.13.2 Services offered
13.1.13.3 Recent developments
13.1.14 FRONTAGE HOLDINGS CORPORATION
13.1.14.1 Business overview
13.1.14.2 Services offered
13.1.14.3 Recent developments
13.1.15 SHANGHAI MEDICILON INC.
13.1.15.1 Business overview
13.1.15.2 Services offered
13.1.15.3 Recent developments
13.1.16 DR. REDDY’S LABORATORIES LTD. (AURIGENE DISCOVERY TECHNOLOGIES)
13.1.16.1 Business overview
13.1.16.2 Services offered
13.1.16.3 Recent developments
13.2 OTHER COMPANIES
13.2.1 SELVITA S.A. (FORMERLY SELVITA CRO S.A.)
13.2.2 VIVA BIOTECH (SHANGHAI) LTD.
13.2.3 TCG LIFESCIENCES PVT LTD.
13.2.4 SHANGHAI CHEMPARTNER CO., LTD.
13.2.5 DOMAINEX LTD.
13.2.6 NUVISAN PHARMA HOLDING GMBH
13.2.7 DALTON PHARMA SERVICES
13.2.8 ARAGEN LIFE SCIENCES PVT. LTD. (FORMERLY GVK BIOSCIENCES PVT. LTD.)
13.2.9 PROMEGA CORPORATION

14 APPENDIX (Page No. - 274)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORT
14.5 AUTHOR DETAILS

LIST OF TABLES (249 Tables)
TABLE 1 DRUG DISCOVERY AND DEVELOPMENT PROCESS OVERVIEW
TABLE 2 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS
TABLE 3 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020
TABLE 4 US: BIOLOGICS GOING OFF-PATENT DURING 2018-2025
TABLE 5 LIST OF ACQUISITIONS
TABLE 6 SUPPLY CHAIN ECOSYSTEM
TABLE 7 REGULATORY SCENARIO
TABLE 8 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 9 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 10 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2019-2026 (USD MILLION)
TABLE 11 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 12 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 13 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 14 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 15 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2019-2026 (USD MILLION)
TABLE 16 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 17 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 18 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 19 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 20 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2019-2026 (USD MILLION)
TABLE 21 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 22 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 23 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 24 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 25 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2019-2026 (USD MILLION)
TABLE 26 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 27 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 28 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 29 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 30 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2019-2026 (USD MILLION)
TABLE 31 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 32 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 33 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 34 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 35 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 36 CHEMISTRY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 37 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 38 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 39 APAC: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 40 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 41 BIOLOGY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 42 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 43 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 44 APAC: BIOLOGY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 45 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 46 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 47 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2019-2026 (USD MILLION)
TABLE 48 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 49 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 50 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 51 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 52 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2019-2026 (USD MILLION)
TABLE 53 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 54 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS DRUG, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 55 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 56 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 57 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 58 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
TABLE 59 ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 60 ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 61 EUROPE: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 62 ASIA PACIFIC: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 63 LATIN AMERICA: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 64 INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 65 NORTH AMERICA: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 66 EUROPE: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 67 ASIA PACIFIC: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 68 LATIN AMERICA: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 69 MEDICINES IN DEVELOPMENT FOR NEUROGENERATIVE DISEASES (2021)
TABLE 70 NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 71 NORTH AMERICA: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 72 EUROPE: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 73 ASIA PACIFIC: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 74 LATIN AMERICA: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 75 DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 76 NORTH AMERICA: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 77 EUROPE: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 78 ASIA PACIFIC: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 79 LATIN AMERICA: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 80 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
TABLE 81 CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 82 NORTH AMERICA: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 83 EUROPE: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 84 ASIA PACIFIC: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 85 LATIN AMERICA: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 86 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019-2026 (USD MILLION)
TABLE 87 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 88 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 89 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 90 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 91 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 92 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2026 (USD MILLION)
TABLE 93 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 94 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 95 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 96 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 97 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 98 TOP PHARMA COMPANIES BY 2020 REVENUE
TABLE 99 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2019-2026 (USD MILLION)
TABLE 100 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 101 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2019-2026 (USD MILLION)
TABLE 102 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 103 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2019-2026 (USD MILLION)
TABLE 104 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 105 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2019-2026 (USD MILLION)
TABLE 106 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 107 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 108 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 109 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 110 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION)
TABLE 111 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 112 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 113 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 114 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 115 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 116 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 117 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 118 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 119 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 120 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 121 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 122 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 123 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 124 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 125 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 126 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 127 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 128 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 129 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 130 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 131 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 132 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 133 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 134 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 135 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 136 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 137 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 138 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 139 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 140 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 141 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 142 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 143 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 144 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 145 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 146 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 147 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 148 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 149 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 150 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 151 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 152 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 153 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 154 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 155 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 156 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 157 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 158 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 159 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 160 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 161 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 162 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 163 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 164 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 165 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 166 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 167 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 168 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 169 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 170 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 171 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 172 ROE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 173 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 174 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 175 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 176 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 177 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 178 APAC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 179 APAC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 180 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 181 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 182 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 183 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 184 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 185 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 186 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 187 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 188 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 189 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 190 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 191 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 192 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 193 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 194 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 195 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 196 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 197 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 198 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 199 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 200 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 201 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 202 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 203 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 204 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 205 LATAM: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 206 LATAM: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 207 LATAM: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 208 LATAM: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 209 LATAM: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 210 LATAM: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 211 LATAM: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 212 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 213 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 214 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 215 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 216 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 217 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 218 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 219 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 220 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 221 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 222 MEA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION)
TABLE 223 MEA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 224 MEA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION)
TABLE 225 MEA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 226 MEA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 227 MEA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION)
TABLE 228 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
TABLE 229 PRODUCT PORTFOLIO ANALYSIS: DRUG DISCOVERY SERVICES MARKET (2020)
TABLE 230 GEOGRAPHIC REVENUE MIX: DRUG DISCOVERY SERVICES MARKET (2020)
TABLE 231 SERVICE LAUNCHES
TABLE 232 DEALS
TABLE 233 EXPANSION
TABLE 234 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
TABLE 235 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
TABLE 236 WUXI APPTEC: BUSINESS OVERVIEW
TABLE 237 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 238 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW
TABLE 239 EVOTEC SE : BUSINESS OVERVIEW
TABLE 240 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW
TABLE 241 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.: BUSINESS OVERVIEW
TABLE 242 PIRAMAL ENTERPRISES LIMITED: BUSINESS OVERVIEW
TABLE 243 SYNGENE INTERNATIONAL LIMITED: BUSINESS OVERVIEW
TABLE 244 CURIA GLOBAL INC.: BUSINESS OVERVIEW
TABLE 245 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
TABLE 246 JUBILANT PHARMOVA LIMITED: BUSINESS OVERVIEW
TABLE 247 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
TABLE 248 SHANGHAI MEDICILON INC.: BUSINESS OVERVIEW
TABLE 249 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW

LIST OF FIGURES (54 Figures)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 3 DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2020
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020
FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2020
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 7 DRUG DISCOVERY SERVICES MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 8 DRUG DISCOVERY SERVICES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
FIGURE 9 DATA TRIANGULATION METHODOLOGY
FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021 VS. 2026 (USD MILLION)
FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021 VS. 2026 (USD MILLION)
FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE DRUG DISCOVERY SERVICES MARKET
FIGURE 15 INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY WILL DRIVE MARKET GROWTH
FIGURE 16 SMALL-MOLECULE DRUGS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN DRUG DISCOVERY MARKET IN 2020
FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES WILL CONTINUE TO DOMINATE THE MARKET IN 2026
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET FROM 2021 TO 2026
FIGURE 20 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 21 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2012-2026
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011-2021
FIGURE 23 NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (2010-2019)
FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION)
FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001-2020)
FIGURE 26 DRUG DISCOVERY SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2026
FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON GROWTH OF THE DRUG DISCOVERY SERVICES MARKET
FIGURE 28 REVENUE SHIFT & NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS
FIGURE 29 VALUE CHAIN ANALYSIS OF DRUG DISCOVERY SERVICES MARKET: HIT-TO-LEAD IDENTIFICATION AND LEAD OPTIMIZATION PHASES ADD MAXIMUM VALUE 66
FIGURE 30 ECOSYSTEM ANALYSIS: DRUG DISCOVERY SERVICES MARKET
FIGURE 31 INCIDENCE OF MAJOR TYPES OF CANCER CASES WORLDWIDE (2020)
FIGURE 32 PHRMA MEMBER COMPANY R&D EXPENDITURE, 2017-2020 (USD BILLION)
FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
FIGURE 34 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES BY REGION (2019 VS. 2020)
FIGURE 35 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
FIGURE 36 KEY PLAYERS STRATEGIES IN THE DRUG DISCOVERY SERVICES MARKET, 2019-2021
FIGURE 37 DRUG DISCOVERY SERVICES MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE DRUG DISCOVERY MARKET, 2018-2020
FIGURE 39 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2020
FIGURE 40 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2020)
FIGURE 42 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2020)
FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2020)
FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2020)
FIGURE 45 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2020)
FIGURE 46 EVOTEC SE: COMPANY SNAPSHOT (2020)
FIGURE 47 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2020)
FIGURE 48 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.: COMPANY SNAPSHOT (2020)
FIGURE 49 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2020)
FIGURE 50 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2020)
FIGURE 51 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 52 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2020)
FIGURE 53 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 54 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2020)

この商品のレポートナンバー

0000031297

TOP